Advertisement







Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:2039-2050, doi:10.1016/j.jacc.2009.03.018 (Published online 29 April 2009).
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow All Versions of this Article:
j.jacc.2009.03.018v1
53/22/2039    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, T. Y.
Right arrow Articles by Gillard, J. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tang, T. Y.
Right arrow Articles by Gillard, J. H.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: CLINICAL TRIAL

The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study

Evaluation Using Ultrasmall Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in Carotid Disease

Tjun Y. Tang, MB, BChir*,{dagger}, Simon P.S. Howarth, BMBCh (Oxon)*,{ddagger}, Sam R. Miller, MSc||, Martin J. Graves, MSc*, Andrew J. Patterson, PhD*, Jean-Marie U-King-Im, PhD*, Zhi Y. Li, PhD*, Stewart R. Walsh, MSc{dagger}, Andrew P. Brown, BSc, Peter J. Kirkpatrick, FmedSci{ddagger}, Elizabeth A. Warburton, DM§, Paul D. Hayes, MD{dagger}, Kevin Varty, MD{dagger}, Jonathan R. Boyle, MD{dagger},*, Michael E. Gaunt, MD{dagger}, Andrew Zalewski, PhD# and Jonathan H. Gillard, MD*,*

* University Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
{dagger} Cambridge Vascular Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
{ddagger} Academic Department of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
§ Department of Clinical Neurosciences, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
|| Discovery Biometrics, GlaxoSmithKline, Harlow, United Kingdom
GlaxoSmithKline Clinical Imaging Centre, Imperial College, Hammersmith Hospital, London, United Kingdom
# Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

Manuscript received September 15, 2008; revised manuscript received January 22, 2009, accepted March 2, 2009.

* Reprint requests and correspondence: Dr. Jonathan H. Gillard, Box 219, Level 5, University Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 2QQ, United Kingdom (Email: jhg21{at}cam.ac.uk).

Objectives: The aim of this study was to evaluate the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on carotid plaque inflammation as determined by ultrasmall superparamagnetic iron oxide (USPIO)-enhanced carotid magnetic resonance imaging (MRI). The hypothesis was that treatment with 80 mg atorvastatin would demonstrate quantifiable changes in USPIO-enhanced MRI-defined inflammation within the first 3 months of therapy.

Background: Preliminary studies indicate that USPIO-enhanced MRI can identify macrophage infiltration in human carotid atheroma in vivo and hence may be a surrogate marker of plaque inflammation.

Methods: Forty-seven patients with carotid stenosis >40% on duplex ultrasonography and who demonstrated intraplaque accumulation of USPIO on MRI at baseline were randomly assigned in a balanced, double-blind manner to either 10 or 80 mg atorvastatin daily for 12 weeks. Baseline statin therapy was equivalent to 10 mg of atorvastatin or less. The primary end point was change from baseline in signal intensity ({Delta}SI) on USPIO-enhanced MRI in carotid plaque at 6 and 12 weeks.

Results: Twenty patients completed 12 weeks of treatment in each group. A significant reduction from baseline in USPIO-defined inflammation was observed in the 80-mg group at both 6 weeks ({Delta}SI 0.13; p = 0.0003) and at 12 weeks ({Delta}SI 0.20; p < 0.0001). No difference was observed with the low-dose regimen. The 80-mg atorvastatin dose significantly reduced total cholesterol by 15% (p = 0.0003) and low-density lipoprotein cholesterol by 29% (p = 0.0001) at 12 weeks.

Conclusions: Aggressive lipid-lowering therapy over a 3-month period is associated with significant reduction in USPIO-defined inflammation. USPIO-enhanced MRI methodology may be a useful imaging biomarker for the screening and assessment of therapeutic response to "anti-inflammatory" interventions in patients with atherosclerotic lesions. (Effects of Atorvastatin on Macrophage Activity and Plaque Inflammation Using Magnetic Resonance Imaging [ATHEROMA]; NCT00368589)

Key Words: carotid stenosis • atherosclerosis • USPIO • MRI • inflammation • statin • plaque vulnerability

Abbreviations and Acronyms
  ES = emboli signal
  HDL-C = high-density lipoprotein cholesterol
  LDL = low-density lipoprotein
  LDL-C = low-density lipoprotein cholesterol
  Lp-PLA2 = lipoprotein-associated phospholipase A2
  MRI = magnetic resonance imaging
  ROI = region of interest
  {Delta}SI = ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging signal change
  TCD = transcranial Doppler
  USPIO = ultrasmall superparamagnetic iron oxide


Related Articles

Coronary Aneurysms After Drug-Eluting Stent Implantation: Clinical, Angiographic, and Intravascular Ultrasound Findings
Fernando Alfonso, Maria-José Pérez-Vizcayno, Miguel Ruiz, Alfonso Suárez, Miguel Cazares, Rosana Hernández, Javier Escaned, Camino Bañuelos, Pilar Jiménez-Quevedo, and Carlos Macaya
J. Am. Coll. Cardiol. 2009 53: 2053-2060. [Abstract] [Full Text] [PDF]

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A29. [Full Text] [PDF]

Iron Oxide Magnetic Resonance Imaging for Atherosclerosis Therapeutic Evaluation: Still "Rusty?"
Zahi A. Fayad, Louai Razzouk, Karen C. Briley-Saebo, and Venkatesh Mani
J. Am. Coll. Cardiol. 2009 53: 2051-2052. [Full Text] [PDF]



This article has been cited by other articles:


Home page
CirculationHome page
D. J. Pennell
Cardiovascular Magnetic Resonance
Circulation, February 9, 2010; 121(5): 692 - 705.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. R. Olzinski, G. H. Turner, R. E. Bernard, H. Karr, C. A. Cornejo, K. Aravindhan, B. Hoang, M. A. Ringenberg, P. Qin, K. B. Goodman, et al.
Pharmacological Inhibition of C-C Chemokine Receptor 2 Decreases Macrophage Infiltration in the Aortic Root of the Human C-C Chemokine Receptor 2/Apolipoprotein E-/- Mouse: Magnetic Resonance Imaging Assessment
Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 253 - 259.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol., January 26, 2010; 55(4): 380 - 407.
[Full Text] [PDF]


Home page
J Am Coll Cardiol ImgHome page
P. K. Shah
Imaging Inflammation in Atherosclerosis: Another Step Forward
J. Am. Coll. Cardiol. Img., October 1, 2009; 2(10): 1223 - 1225.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Z. A. Fayad, L. Razzouk, K. C. Briley-Saebo, and V. Mani
Iron Oxide Magnetic Resonance Imaging for Atherosclerosis Therapeutic Evaluation: Still "Rusty?"
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2051 - 2052.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement